NNMT Inhibitor / NAD+ Enhancer

5-Amino-1MQ

A small molecule inhibitor of NNMT (Nicotinamide N-Methyltransferase) — an enzyme that degrades NAD+ precursors and promotes fat cell differentiation. Inhibiting NNMT simultaneously raises cellular NAD+ and reduces adipogenesis without stimulating the CNS.

fat-lossmetaboliclongevity
Tier CUse caution — limited human data
Evidence gradeDAnecdotal / In vitro only
BH

Reviewed & fact-checked by

BiohackingHub Research Team

Editorial Research Team · Last updated: March 26, 2026

Verified

The NNMT Problem

NNMT (Nicotinamide N-Methyltransferase) is an enzyme that methylates nicotinamide (NAM) — converting it to 1-methylnicotinamide (MeNAM). This process has two significant consequences for metabolism and longevity:

NAD+ depletion: By consuming NAM — a key NAD+ precursor — NNMT reduces the availability of substrate for NAD+ synthesis. Higher NNMT activity means lower cellular NAD+ levels.

Fat cell promotion: NNMT is highly expressed in adipose tissue and plays a key role in adipocyte differentiation. High NNMT activity promotes the formation of new fat cells and maintains the metabolic signature of obesity. Importantly, NNMT expression is elevated in obese individuals compared to lean controls.

Mechanism of 5-Amino-1MQ

5-Amino-1MQ is a selective, membrane-permeable small molecule inhibitor of NNMT. By blocking NNMT activity, it simultaneously: []

  • Spares NAM → more substrate available for NAD+ synthesis
  • Reduces adipogenesis → fewer new fat cells form
  • Shifts adipocyte metabolism → white adipose tissue takes on more brown fat characteristics
  • Reduces fat cell size → existing adipocytes shrink

Mouse studies showed 5-Amino-1MQ reduced body weight and fat mass in diet-induced obese mice, with improvements in insulin sensitivity and lipid profiles — without any reduction in food intake. This "passive" fat loss mechanism distinguishes it from stimulant-based thermogenics.

Honest Assessment of Human Evidence

No human RCTs exist. All efficacy claims are extrapolated from cell culture and mouse studies. The mechanism is scientifically sound, but translation from mouse to human is never guaranteed — and NNMT plays complex roles in cancer biology that are not fully understood.

The Tier C rating reflects the limited human data and incomplete understanding of long-term safety. This is a compound for experienced biohackers willing to accept higher uncertainty.

The NAD+ Angle

The combination of NNMT inhibition (5-Amino-1MQ) with NAD+ precursor supplementation (NMN) creates a dual-mechanism approach: reduce NAD+ degradation while increasing NAD+ synthesis. This is analogous to simultaneously plugging a drain and turning up the tap.

Stacking Interactions

How 5-Amino-1MQ interacts with other compounds

+
NMN (Nicotinamide Mononucleotide)Synergisticweak evidence

NMN 500mg + 5-Amino-1MQ 100mg is a rational NAD+ maximisation stack. Take together in the morning.

+
Berberine (Liposomal)Synergisticanecdotal evidence

Both compounds target metabolic health via independent pathways. Rational combination for metabolic syndrome protocols.

Safety Profile — Tier C

Use caution — limited human data

Contraindications

  • Pregnancy or breastfeeding (no safety data)
  • Active hepatic disease (NNMT is highly expressed in liver)
  • History of cancer (NNMT plays complex roles in tumour biology)

Side Effects

  • Very limited human safety data available
  • Reported: mild GI discomfort, headache, fatigue in some users
  • Unknown long-term effects

Drug Interactions

Limited data. NNMT inhibition affects methylation pathways — theoretical interactions with drugs metabolised via methyltransferases

Research References

  1. [1]PubMed: 32433949
  2. [2]PubMed: 30770397